The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

Receipt of zoster vaccine reduces probability of new dementia diagnosis over seven-year period by 3.5 percentage points.

HealthDay News — Health experts are warning that whooping cough, also known as pertussis, is making a dangerous comeback. Cases are rising across the country, and Louisiana recently reported that 2 ...

Program increases receipt of follow-up colonoscopy among persons aged 50 to 75 years with an abnormal stool test result.

The Company expects to have topline data from 2 trials assessing the effect of reproxalap on dry eye disease symptoms available in the second quarter of 2025.

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

HealthDay News — Use of hormonal contraceptives postpartum is associated with an increased risk for developing postpartum depression, according to a study published online March 31 in JAMA Network ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

"If artificial intelligence is going to be impactful, it needs to be better than the human eye," said the lead researcher.

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.